Mental Health and Advocacy in Pediatric Migraine
Episode 67, Jul 01, 2022, 09:00 AM
Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Serena L. Orr, MD, MSc, a pediatric neurologist and headache specialist at the University of Calgary and Alberta Children's. She spoke about the recent work she's done looking into mental health conditions among pediatric patients with migraine, as well as how the field has progressed in managing the disease and advocating for these individuals.
In this episode, we spoke with Serena L. Orr, MD, MSc, a pediatric neurologist and headache specialist at the University of Calgary and Alberta Children's. She spoke about the recent work she's done looking into mental health conditions among pediatric patients with migraine, as well as how the field has progressed in managing the disease and advocating for these individuals.
Episode Breakdown:
- 1:25 – Overview of systematic review of depressive and anxiety symptoms in pediatric migraine
- 5:30 – Clinical implications of the data and the need for advocacy for this population
- 8:50 – Possible differences between children and adolescents
- 10:15 – Remaining questions for this area of research
- 13:20 – The needs from a research funding perspective
- 15:05 – Neurology News Minute
- 17:20 – Shifting the paradigm of pediatric headache research
- 21:35 – Challenges in awareness despite patient population size
- 24:15 – Exposure to headache medicine education among trainees
- 26:25 – Conducting clinical trials in pediatric migraine
Check out Medical World News' Second Opinion only at medicalworldnews.com
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- FDA Advisory Committee Votes Down Pimavanserin's Efficacy in AD Psychosis Ahead of PDUFA
- Parkinson Disease Symptom Data Tool StrivePD Receives FDA Clearance
- AbbVie Submits Supplemental New Drug Application for Atogepant in Chronic Migraine
- FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns
- FDA Pauses Tolebrutinib Trials in MS, Myasthenia Gravis Over Liver Injuries
Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.